Screener
Castle Biosciences CSTL Interest Income
Interest Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Amortization of acquired intangible assets | 2,226 | 28,325 |
| Total operating expenses, net | 102,086 | 115,916 |
| Operating loss | (18,407) | (27,928) |
| Interest income | 2,545 | 3,099 |
| Net gains (losses) on equity securities | 2,022 | (1,425) |
| Interest expense | (134) | (17) |
| Other loss | (439) | — |
| Loss before income taxes | (14,413) | (26,271) |
Item 1. Financial Statements.
FAQ
- What is Castle Biosciences's interest income?
- Castle Biosciences (CSTL) reported interest income of $2.55M in Q1 2026.
- How has Castle Biosciences's interest income changed year-over-year?
- Castle Biosciences's interest income decreased by 17.9% year-over-year, from $3.1M to $2.55M.
- What is the long-term trend for Castle Biosciences's interest income?
- Over 4 years (2021 to 2025), Castle Biosciences's interest income has grown at a 262.7% compound annual growth rate (CAGR), from $68K to $11.77M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about Castle Biosciences's interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude